KNOXVILLE, Tenn., June 14 /PRNewswire-FirstCall/ -- Provectus Pharmaceuticals (BULLETIN BOARD: PVCT) , an innovative pharmaceutical company engaged in the research and development of breakthrough technologies for cancer, psoriasis and other serious diseases, announced today that Kevin Richardson, a cancer activist and member of the popular band, the Backstreet Boys, has become a corporate spokesperson for the Company. Richardson became involved with Provectus through his introduction to Peter Culpepper, CFO of Provectus, whose daughter Victoria, a young cancer survivor, was the Honorary Survivor at the Relay For Life fundraising event in East Tennessee.
Richardson and the Backstreet Boys were scheduled to attend the Relay For Life fundraiser this past weekend, which was sponsored by both the American Cancer Society and Provectus, however, their appearance was cancelled due to mechanical problems with their scheduled flight.
Richardson is an active cancer patient advocate, especially in the area of colon cancer awareness and prevention, a cause that has become particularly important to him since losing his father, Jerald Wayne Richardson, to the disease in 1991. In 2001, Kevin Richardson joined politicians from New York and other states in Washington, D.C. to introduce the "Eliminate Colorectal Cancer Act," which was established to promote education and early detection and treatment of colon cancer.
About Relay For Life
The Relay For Life is an overnight gathering of celebration and remembrance. The event raises funds for the fight against cancer, a disease that will affect one in three Americans in their lifetime, and will result in more than 1 million new diagnoses this year. This year, 3 million Relay For Life participants in 4,200 local communities across the country will raise millions of dollars to fuel the American Cancer Society's mission.
About Provectus Pharmaceuticals Inc.
Provectus Pharmaceuticals Inc. is a pioneering pharmaceutical company actively engaged in the design, development and marketing of pharmaceutical technologies for the treatment of liver, breast and prostate cancer and metastatic melanoma. In addition, Provectus is developing treatments for skin diseases such as psoriasis. Provectus' patented approach targets abnormal or diseased cells in its design of treatments for dermatological diseases, in particular, chronic, severe cases of psoriasis and eczema. Clinical studies are already in process for the Company's topical agent Xantryl(TM). In addition, certain skin cancers may be targeted and treated more safely and effectively using Xantryl. Although still in the early stages of development, pre-clinical studies have shown that Provecta(TM), when injected directly into a tumor, not only kills the treated tumor but also may protect against its spreading throughout the body.
The Company's offices and laboratory are located at 7327 Oak Ridge Highway, Suite A, Knoxville, TN 37931; telephone: 865-769-4011. For more
information, contact the Company at
This release and others statements issued or made from time to time by the company or its representatives contain comments that may constitute forward- looking statements. Those include statements regarding the intent, belief or current expectations of the company and members of its management teams, as well as the assumptions on which the statements are based. Prospective investors are cautioned that such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward- looking statements.
